Institutional shares held 51.7 Million
201K calls
179K puts
Total value of holdings $8.67B
$33.7M calls
$30M puts
Market Cap $8.54B
50,863,300 Shares Out.
Institutional ownership 101.57%
# of Institutions 646


Latest Institutional Activity in CRL

Top Purchases

Q3 2025
Ameriprise Financial Inc Shares Held: 614K ($103M)
Q3 2025
National Bank Of Canada Shares Held: 947K ($159M)
Q3 2025
D. E. Shaw & Co., Inc. Shares Held: 960K ($161M)
Q3 2025
Harris Associates L P Shares Held: 1.47M ($247M)
Q3 2025
Lsv Asset Management Shares Held: 298K ($50M)

Top Sells

Q3 2025
Nomura Holdings Inc Shares Held: 806K ($135M)
Q3 2025
Wellington Management Group LLP Shares Held: 3.19M ($535M)
Q3 2025
Assenagon Asset Management S.A. Shares Held: 32.3K ($5.42M)
Q3 2025
Citadel Advisors LLC Shares Held: 118K ($19.8M)
Q3 2025
Jpmorgan Chase & CO Shares Held: 317K ($53.2M)

About CRL

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.


Insider Transactions at CRL

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
114K Shares
From 19 Insiders
Grant, award, or other acquisition 106K shares
Open market or private purchase 7.59K shares
Sell / Disposition
22.3K Shares
From 11 Insiders
Payment of exercise price or tax liability 15.1K shares
Bona fide gift 815 shares
Open market or private sale 6.38K shares

Track Institutional and Insider Activities on CRL

Follow CHARLES RIVER LABORATORIES INTERNATIONAL, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRL shares.

Notify only if

Insider Trading

Get notified when an Charles River Laboratories International, Inc. insider buys or sells CRL shares.

Notify only if

News

Receive news related to CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Track Activities on CRL